Skip to main content

Super navigation

  • Newsroom
    • The Latest
    • Press releases
    • argenx Stories
    • Downloadable assets
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Cultural Pillars
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us
Home

Secondary navigation additional

  • Contact

Secondary/mobile navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Cultural Pillars
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us

Breadcrumb

  1. Home
  2. Press Releases
  • Twitter
  • Facebook
  • LinkedIn
  • WhatsApp

Press Releases

  • (-) Any
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
Reset

2014

April 3, 2014
arGEN-X Appoints Dr Werner Lanthaler to its Supervisory Board
January 12, 2014
arGEN-X receives two preclinical milestone payments under collaboration with Shire
January 6, 2014
arGEN-X starts Phase Ib expansion cohorts with ARGX-110, a novel anti-CD70 antibody, in cancer patients

2013

December 16, 2013
ARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase Ib cancer study
November 3, 2013
arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer
November 3, 2013
arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B
September 18, 2013
arGEN-X reaches milestone in SIMPLE Antibody™ research and product development collaboration with Shire
September 16, 2013
arGEN-X initiates Phase Ib study of ARGX-111 in cancer
September 11, 2013
arGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7
August 5, 2013
arGEN-X grants license to its NHance™ antibody half-life extension technology
April 25, 2013
arGEN-X to Present at Upcoming Ninth Annual PEGS 2013
March 24, 2013
arGEN-X announces preclinical development of ARGX-112 for dermatology

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Current page 28
  • Page 29
  • Page 30
  • Page 31
  • Next page Next ›
  • Last page Last »
Home
  • Home
  • Contact us

Footer navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Cultural Pillars
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us
2023 © argenx
Disclaimer
Privacy policy
Regulations